State Street SPDR S&P Biotech ETF (XBI) rated Buy with 8%-14% returns expected despite prior 76% rally

The State Street SPDR S&P Biotech ETF (XBI) is rated as a Buy, with an expected total return of 8% to 14% over the next 6 to 12 months, even after a strong 76% gain in the past year. XBI's modified equal-weight structure provides broad exposure to over 150 biotech companies, benefiting from ongoing mergers and acquisitions as well as improved access to capital. While recent large pharmaceutical acquisitions and selective capital flows support the positive outlook, investors should be aware of high volatility and the likelihood of more moderate returns ahead. Risks include tightening financing conditions, a slowdown in mergers and acquisitions, and potential underperformance of smaller biotech firms. Caution is advised if the IBB ETF outperforms, as it may indicate increased volatility for XBI.